Financial News
Latest News about Weight Loss Drug
Recent news which mentions Weight Loss Drug
From Benzinga
Novo Nordisk, Eli Lilly Could Face Downward Pressure Despite Market Dominance From Potentially 16 New Obesity Drugs: See The Names
October 11, 2024
From Benzinga
Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes
September 25, 2024
From Benzinga
Viking Therapeutics Stock Could Soar 45% Ahead Of Key Weight Loss Drug Readout: JPMorgan
September 11, 2024
Tickers
VKTX
From Benzinga
Novo Nordisk Vs. Eli Lilly: Beyond The Weight-Loss Drug Battle
August 21, 2024
From Benzinga
From Benzinga
Eli Lilly's Popular Weight Loss/Diabetes Drug Tirzepatide Cuts Heart Failure Risk By 38%, Pivotal Phase 3 Study Shows
August 01, 2024
From Benzinga
Roche Highlights Encouraging Data From Newly-Acquired Second Weight Loss Drug Candidate In Early-Stage Study
July 17, 2024
From Benzinga
Novo Nordisk Sues Additional US Clinics Against Fake Semaglutide Products Used For Weight Loss, Diabetes
May 31, 2024
From Benzinga
Novo Nordisk Faces Scrutiny Over High Prices of Ozempic And Wegovy, Blames US Health System
May 28, 2024
From Benzinga
From Benzinga
From Benzinga
Genetic Profile Key To Novo Nordisk's Wegovy's Weight-Loss Effectiveness, Study Reveals
May 20, 2024
From Benzinga
From Benzinga
Eli Lilly Struggles To Keep Pace With Mounjaro, Zepbound Demand: 'Currently Unavailable' On Amazon Pharmacy
April 03, 2024
From Benzinga
From Benzinga
Take Your Ozempic: Why Late Entry Of Rival Weight-Loss Drugs Won't Floor Novo, Eli Shares
January 31, 2024
From Benzinga
Is Your Weight-loss Medication Genuine? Demand For Drugs From Novo Nordisk And Eli Lilly Leads To Surge In Counterfeits
October 21, 2023
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
